Clinical Features and Outcomes of Bacteremia Caused by Enterococcus casseliflavus and Enterococcus gallinarum: Analysis of 56 Cases

Clinical Infectious Diseases

Volumn 38, Issue 1, 2004, Pages 53-61

  Choi, Sang Ho ^a   Lee, Sang Oh ^a   Kim, Tae Hyong ^a   Chung, Jin Won ^a   Choo, Eun Ju ^a   Kwak, Yee Gyung ^a   Kim, Mi Na ^b   Kim, Yang Soo ^a   Woo, Jun Hee ^a   Ryu, Jiso ^a   Kim, Nam Joong ^a,c  

^a University of Ulsan   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Asan Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; PENICILLIN G; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; VANCOMYCIN;

ADULT; ARTICLE; BACTEREMIA; BACTERIAL VIRULENCE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENTEROCOCCUS CASSELIFLAVUS; ENTEROCOCCUS GALLINARUM; FEMALE; HEPATOBILIARY DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BILIARY TRACT DISEASES; ENTEROCOCCUS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 9144232448     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/380452     Document Type: Article

References (55)

1. Vincent S, Knight RG, Green M, Sahm DF, Shlaes DM. Vancomycin susceptibility and identification of motile enterococci. J Clin Microbiol 1991; 29:2335-7.
2. Leclercq R, Dutka-Malen S, Duval J, Courvalin P. Vancomycin resistance gene vanC is specific to Enterococcus gallinarum. Antimicrob Agents Chemother 1992; 36:2005-8.
3. Toye B, Shymanski J, Bobrowska M, Woods W, Ramotar K. Clinical and epidemiological significance of enterococci intrinsically resistant to vancomycin (possessing the vanC genotype). J Clin Microbiol 1997; 35:3166-70.
4. Murray BE. Vancomycin-resistant enterococci. Am J Med 1997; 102: 284-93.
5. Green M, Barbadora K, Michaels M. Recovery of vancomycin-resistant gram-positive cocci from pediatric liver transplant recipients. J Clin Microbiol 1991; 29:2503-6.
6. Kaplan AH, Gilligan PH, Facklam RR. Recovery of resistant enterococci during vancomycin prophylaxis. J Clin Microbiol 1988; 26:1216-8.
7. Van Goethem GF, Louwagie BM, Simoens MJ, Vandeven JM, Verhaegen JL, Boogaerts MA. Enterococcus casseliflavus septicemia in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 1994; 13: 519-20.
8. Ruess M, Sander A, Hentschel R, Berner R. Enterococcus casseliflavus septicaemia in a preterm neonate. Scand J Infect Dis 2002; 34:471-2.
9. Sahm DF, Free L, Smith C, Eveland M, Mundy LM. Rapid characterization schemes for surveillance isolates of vancomycin-resistant enterococci. J Clin Microbiol 1997; 35:2026-30.
10. van Horn KG, Gedris CA, Rodney KM. Selective isolation of vancomycin-resistant enterococci. J Clin Microbiol 1996; 34:924-7.
11. Nelson RR. Intrinsically vancomycin-resistant gram-positive organisms: clinical relevance and implications for infection control. J Hosp Infect 1999; 42:275-82.
12. Facklam RR, Collins MD. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 1989; 27:731-4.
13. Carvalho MG, Teixeira LM, Facklam RR. Use of tests for acidification of methyl-α-D-glucopyranoside and susceptibility to efrotomycin for differentiation of strains of Enterococcus and some related genera. J Clin Microbiol 1998; 36:1584-7.
14. Iwen PC, Kelly DM, Linder J, Hinrichs SH. Revised approach for identification and detection of ampicillin and vancomycin resistance in Enterococcus species by using MicroScan panels. J Clin Microbiol 1996; 34:1779-83.
15. Clark NC, Teixeira LM, Facklam RR, Tenover FC. Detection and differentiation of vanC-1, vanC-2, and vanC-3 glycopeptide resistance genes in enterococci. J Clin Microbiol 1998; 36:2294-7.
16. Devriese LA, Pot B, Kersters K, Lauwers S, Haesebrouck F. Acidification of methyl-α-D-glucopyranoside: a useful test to differentiate Enterococcus casseliflavus and Enterococcus gallinarum from Enterococcus faecium species group and from Enterococcus faecalis. J Clin Microbiol 1996; 34:2607-8.
17. Turenne CY, Hoban DJ, Karlowsky JA, Zhanel GG, Kabani AM. Screening of stool samples for identification of vancomycin-resistant Enterococcus isolates should include the methyl-α-D-glucopyranoside test to differentiate nonmotile Enterococcus gallinarum from E. faecium. J Clin Microbiol 1998; 36:2333-5.
18. Ruoff KL, de la Maza L, Murtagh MJ, Spargo JD, Ferraro MJ. Species identities of enterococci isolated from clinical specimens. J Clin Microbiol 1990; 28:435-7.
19. Bryce EA, Zemcov SJ, Clarke AM. Species identification and antibiotic resistance patterns of the entetococci. Eur J Clin Microbiol Infect Dis 1991; 10:745-7.
20. Miele A, Goldstein BP, Bandera M, Jarvis C, Resconi A, Williams RJ. Differential susceptibilities of enterococcal species to elfamycin antibiotics. J Clin Microbiol 1994; 32:2016-8.
21. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol 1995; 33:24-7.
22. Patel R, Uhl JR, Kohner P, Hopkins MK, Cockerill FR 3rd. Multiplex PCR detection of vanA, vanB, vanC-1, and vanC-2/3 genes in enterococci. J Clin Microbiol 1997; 35:703-7.
23. Patel R, Piper KE, Rouse MS, et al. Determination of 16S rRNA sequences of enterococci and application to species identification of non-motile Enterococcus gallinarum isolates. J Clin Microbiol 1998; 36: 3399-407.
24. Maki DG, Agger WA. Enterococcal bacteremia: clinical features, the risk of endocarditis, and management. Medicine (Baltimore) 1988; 67: 248-69.
25. Caballero-Granado FJ, Becerril B, Cuberos L, Bernabeu M, Cisneros JM, Pachon J. Attributable mortality rate and duration of hospital stay associated with enterococcal bacteremia. Clin Infect Dis 2001; 32: 587-94.
26. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999; 20:318-23.
27. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med 2001; 135:484-92.
28. Peset V, Tallon P, Sola C, et al. Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. Eur J Clin Microbiol Infect Dis 2000; 19:742-9.
29. Garbutt JM, Ventrapragada M, Littenberg B, Mundy LM. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 2000; 30:466-72.
30. Patterson JE, Sweeney AH, Simms M, et al. An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome. Medicine (Baltimore) 1995; 74:191-200.
31. Reid KC, Cockerill IF, Patel R. Clinical and epidemiological features of Enterococcus casseliflavus/flavescens and Enterococcus gallinarum bacteremia: a report of 20 cases. Clin Infect Dis 2001; 32:1540-6.
32. Ratanasuwan W, Iwen PC, Hinrichs SH, Rupp ME. Bacteremia due to motile Enterococcus species: clinical features and outcomes. Clin Infect Dis 1999; 28:1173-7.
33. McCabe WR, Jackson GG. Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med 1962; 110:847-55.
34. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992; 101:1481-3.
35. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995; 273:117-23.
36. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-90.
37. NCCLS. Performance standards for antimicrobial susceptibility testing: ninth informational supplement M100-S9. Wayne, PA: NCCLS, 1999.
38. Krcmery V, Bilikova E, Svetlansky I, Kovacicova G. Is vancomycin resistance in enterococci predictive of inferior outcome of enterococcal bacteremia? Clin Infect Dis 2001; 32:1110-2.
39. Swenson JM, Clark NC, Ferraro MJ, et al. Development of a standardized screening method for detection of vancomycin-resistant enterococci. J Clin Microbiol 1994; 32:1700-4.
40. Cartwright CP, Stock F, Fahle GA, Gill VJ. Comparison of pigment production and motility tests with PCR for reliable identification of intrinsically vancomycin-resistant enterococci. J Clin Microbiol 1995; 33:1931-3.
41. Van Horn KG, Rodney KM. Colonization and microbiology of the motile enterococci in a patient population. Diagn Microbiol Infect Dis 1998; 31:525-30.
42. Edlund C, Barkholt L, Olsson-Liljequist B, Nord CE. Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin Infect Dis 1997; 25:729-32.
43. Antalek MD, Mylotte JM, Lesse AJ, Sellick JA Jr. Clinical and molecular epidemiology of Enterococcus faecalis bacteremia, with special reference to strains with high-level resistance to gentamicin. Clin Infect Dis 1995; 20:103-9.
44. Suppola JP, Kuikka A, Vaara M, Valtonen VV. Comparison of risk factors and outcome in patients with Enterococcus faecalis vs Enterococcus faecium bacteraemia. Scand J Infect Dis 1998; 30:153-7.
45. Noskin GA, Peterson LR, Warren JR. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 1995; 20:296-301.
46. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995; 172:993-1000.
47. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996; 22: 663-70.
48. Zaas AK, Song X, Tucker P, Perl TM. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 2002; 35:1139-46.
49. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998; 158:522-7.
50. Vergis EN, Shankar N, Chow JW, et al. Association between the presence of enterococcal virulence factors gelatinase, hemolysin, and enterococcal surface protein and mortality among patients with bacteremia due to Enterococcus faecalis. Clin Infect Dis 2002; 35:570-5.
51. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998; 26:1127-33.
52. Dutka-Malen S, Blaimont B, Wauters G, Courvalin P. Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother 1994; 38: 1675-7.
53. Liassine N, Frei R, Jan I, Auckenthaler R. Characterization of glycopeptide-resistant enterococci from a Swiss hospital. J Clin Microbiol 1998; 36:1853-8.
54. Billot-Klein D, Gutmann L, Sable S, Guittet E, van Heijenoort J. Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant VANB-type Enterococcus D366 and of the naturally glycopeptide-resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Enterococcus gallinarum. J Bacteriol 1994; 176:2398-405.
55. Sahm DF, Free L, Handwerger S. Inducible and constitutive expression of vanC-1-encoded resistance to vancomycin in Enterococcus gallinarum. Antimicrob Agents Chemother 1995; 39:1480-4.